Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Anti-EGFR/IL-13R alpha 2 CAR T cell therapy - Tmunity Therapeutics/University of Pennsylvania

Next Previous
Drug Profile

Anti-EGFR/IL-13R alpha 2 CAR T cell therapy - Tmunity Therapeutics/University of Pennsylvania

Alternative Names: Anti-EGFR/IL-13Rα2 CAR T cell therapy; Anti-Epidermal growth factor receptor/ Interleukin 13 Receptor subunit alpha 2 CAR-T therapy; CART-EGFR-IL13Ra2; TmEGFR/IL13Rα2 01 CAR-T

Latest Information Update: 10 Oct 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Tmunity Therapeutics; University of Pennsylvania
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Glioblastoma

Most Recent Events

  • 06 Oct 2025 University of Pennsylvania plans a phase I trial for Glioblastoma (Recurrent) in USA (NCT07209241)
  • 29 Sep 2025 Anti-EGFR/IL-13R alpha 2 CAR T cell therapy is still in phase I clinical trials in Glioblastoma (Recurrent) in USA (Intrathecal) (NCT05168423)
  • 31 Aug 2025 Tmunity Therapeutics in collaboration with University of Pennsylvania completes enrollment in phase I trial in Glioblastoma (Recurrent) in USA (Intrathecal) (NCT05168423)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top